Patents by Inventor Aya Jakobovits

Aya Jakobovits has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AND RELATED MOLECULES THAT BIND TO 161P2F10B PROTEINS
    Publication number: 20090022663
    Abstract: Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.
    Type: Application
    Filed: August 21, 2008
    Publication date: January 22, 2009
    Inventors: Aya JAKOBOVITS, Steven B. Kanner, Pia M. Challita-Eid, Juan J. Perez-Villar, Daulet Satpaev, Arthur B. Raitano, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Xiao-Chi Jia, Jean Gudas
  • PSCA prostate stem cell antigen and uses thereof
    Publication number: 20080318253
    Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
    Type: Application
    Filed: August 21, 2002
    Publication date: December 25, 2008
    Inventors: Robert Reiter, Owen Witte, Douglas Saffran, Aya Jakobovits
  • Antibody that binds zinc transporter protein 108P5H8
    Patent number: 7459539
    Abstract: A novel gene (designated 108P5H8) and its encoded protein, and variants thereof, are described wherein 108P5H8 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 108P5H8 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 108P5H8 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 191P1E1B can be used in active or passive immunization.
    Type: Grant
    Filed: December 17, 2001
    Date of Patent: December 2, 2008
    Assignee: Agensys, Inc.
    Inventors: Pia M. Challita-Eid, Mary Faris, Daniel E. H. Afar, Rene S. Hubert, Steve Chappell Mitchell, Elana Levin, Karen Jane Meyrick Morrison, Arthur B. Raitano, Aya Jakobovits
  • Nucleic acid and corresponding protein entitled 161P5C5 useful in treatment and detection of cancer
    Publication number: 20080280822
    Abstract: A novel gene (designated 161P5C5) and its encoded protein, and variants thereof, are described wherein 161P5C5 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table 1. Consequently, 161P5C5 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P5C5 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P5C5 can be used in active or passive immunization.
    Type: Application
    Filed: May 26, 2006
    Publication date: November 13, 2008
    Applicant: Agensys, Inc.
    Inventors: Pia M. Challita-Eid, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Wangmao Ge, Aya Jakobovits
  • Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer
    Patent number: 7449548
    Abstract: A novel gene (designated 193P1E1B) and its encoded protein, and variants thereof, are described wherein 193P1E1B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 193P1E1B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 193P1E1B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 191P1E1B can be used in active or passive immunization.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: November 11, 2008
    Assignee: Agensys, Inc.
    Inventors: Arthur B. Raitano, Pia M. Challita-Eid, Mary Faris, Rene S Hubert, Wangmao Ge, Aya Jakobovits
  • Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
    Publication number: 20080267872
    Abstract: A novel gene 098P4B6 (also designated STEAP-2) and its encoded protein, and variants thereof, are described wherein 98P4B6 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 98P4B6 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 98P4B6 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 98P4B6 can be used in active or passive immunization.
    Type: Application
    Filed: September 22, 2006
    Publication date: October 30, 2008
    Inventors: Arthur B. Raitano, Wangmag Ge, Aya Jakobovits, Pia M. Challita-Eid, Mary Faris
  • Production of a multimeric protein by cell fusion method
    Patent number: 7429380
    Abstract: The present invention features a method of producing a multimeric protein from a hybrid cell formed from the fusion of two or more cells, each of which cell is engineered to express one component of the multimeric protein, as well as a method for screening for successful fusion of the cells to produce a desired hybrid cell. The methods of the invention are widely applicable to the production of proteins having two or more components.
    Type: Grant
    Filed: November 20, 2003
    Date of Patent: September 30, 2008
    Assignee: Amgen Fremont Inc.
    Inventors: Nobuaki Hori, Claude Geoffrey Davis, Krisztina M. Zsebo, Aya Jakobovits
  • Transgenic mammals having human Ig loci including plural VH and VK regions and antibodies produced therefrom
    Publication number: 20080235814
    Abstract: The present invention relates to transgenic non-human animals that are engineered to contain human immunoglobulin gene loci. In particular, animals in accordance with the invention possess human Ig loci that include plural variable (VH and V?) gene regions. Advantageously, the inclusion of plural variable region genes enhances the specificity and diversity of human antibodies produced by the animal. Further, the inclusion of such regions enhances and reconstitutes B-cell development to the animals, such that the animals possess abundant mature B-cells secreting extremely high affinity antibodies.
    Type: Application
    Filed: October 14, 2005
    Publication date: September 25, 2008
    Inventors: Aya Jakobovits, Raju Kucherlapati, Susan Klapholz, Michael J. Mendez, Larry Green
  • Nucleic acid and corresponding protein entitled 121P2A3 useful in treatment and detection of cancer
    Publication number: 20080233598
    Abstract: A novel gene (designated 121P2A3) and its encoded protein, and variants thereof, are described wherein 121P2A3 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 121P2A3 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 121P2A3 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 121P2A3 can be used in active or passive immunization.
    Type: Application
    Filed: February 6, 2007
    Publication date: September 25, 2008
    Applicant: AGENSYS, INC.
    Inventors: Pia M. Challita-Eid, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Steve Chappell Mitchell, Daniel E. H. Afar, Doulas Saffran, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Wangmao Ge, Aya Jakobovits
  • Antibodies and related molecules that bind to 161P2F10B proteins
    Patent number: 7427399
    Abstract: Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: September 23, 2008
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Steven B. Kanner, Pia M. Challita-Eid, Juan J. Perez-Villar, Daulet Satpaev, Arthur B. Raitano, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Xiao-chi Jia, Jean Gudas
  • 125P5C8: TISSUE SPECIFIC PROTEIN HIGHLY EXPRESSED IN VARIOUS CANCERS
    Publication number: 20080193458
    Abstract: A novel gene (designated 125P5C8) and its encoded protein are described. While 125P5C8 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed multiple cancers including prostate, bladder, kidney and colon cancers. Consequently, 125P5C8 provides a diagnostic and/or therapeutic target for cancers, and the 125P5C8 gene or fragment thereof, or its encoded protein or a fragment thereof used to elicit an immune response.
    Type: Application
    Filed: September 18, 2007
    Publication date: August 14, 2008
    Inventors: Mary Faris, Pia M. Challita-Eid, Steve Chappell Mitchell, Daniel E.H. Afar, Arthur B. Raitano, Aya Jakobovits
  • PSCA: prostate stem cell antigen and uses thereof
    Patent number: 7407656
    Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
    Type: Grant
    Filed: January 29, 2004
    Date of Patent: August 5, 2008
    Assignees: The Regents of the University of California, Agensys, Inc.
    Inventors: Robert E. Reiter, Owen N. Witte, Douglas C. Saffran, Aya Jakobovits
  • NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 202P5A5 USEFUL IN TREATMENT AND DETECTION OF CANCER
    Publication number: 20080181885
    Abstract: A novel gene 202P5A5 and its encoded protein, and variants thereof, are described wherein 202P5A5 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 202P5A5 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 202P5A5 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 202P5A5 can be used in active or passive immunization.
    Type: Application
    Filed: October 11, 2006
    Publication date: July 31, 2008
    Inventors: Arthur Raitano, Mary Faris, Pia Challita-Eid, Aya Jakobovits, Wangmao Ge
  • Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
    Patent number: 7405290
    Abstract: A gene (designated 161P2F10B) and its encoded protein are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit a humoral or cellular immune response.
    Type: Grant
    Filed: June 2, 2004
    Date of Patent: July 29, 2008
    Assignee: Agensys, Inc.
    Inventors: Pia M. Challita-Eid, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Karen Jane Meyrick Morrison, Aya Jakobovits
  • Antibodies to tumor associated proteins
    Publication number: 20080167448
    Abstract: A novel gene 024P4C12 (also designated 24P4C12) and its encoded protein, and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 24P4C12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 24P4C12 can be used in active or passive immunization.
    Type: Application
    Filed: August 20, 2007
    Publication date: July 10, 2008
    Inventors: Arthur B. Raitano, Karen Jane Meyrick Morrison, Wangmao Ge, Pia M. Challita-Eid, Aya Jakobovits
  • Transgenic mammals having human Ig loci including plural Vh and Vk regions and antibodies produced therefrom
    Publication number: 20080098490
    Abstract: The present invention relates to transgenic non-human animals that are engineered to contain human immunoglobulin gene loci. In particular, animals in accordance with the invention possess human Ig loci that include plural variable (VH and V?) gene regions. Advantageously, the inclusion of plural variable region genes enhances the specificity and diversity of human antibodies produced by the animal. Further, the inclusion of such regions enhances and reconstitutes B-cell development to the animals, such that the animals possess abundant mature B-cells secreting extremely high affinity antibodies.
    Type: Application
    Filed: August 20, 2007
    Publication date: April 24, 2008
    Inventors: Aya Jakobovits, Raju Kucherlapati, Susan Klapholz, Michael Mendez, Larry Green
  • Methods to inhibit growth of prostate cancer cells
    Patent number: 7361338
    Abstract: A novel gene (designated 101P3A11 or PHOR-1) and its encoded protein, and variants thereof, are described wherein 101P3A11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 101P3A11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 101P3A11 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 101P3A11 can be used in active or passive immunization.
    Type: Grant
    Filed: May 15, 2002
    Date of Patent: April 22, 2008
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Mary Faris, Arthur B. Raitano, Robert Kendall Morrison, Douglas Saffran, Wangmao Ge, Pia M. Challita-Eid
  • Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
    Patent number: 7358353
    Abstract: A novel gene (designated 158P1D7) and its encoded protein are described. While 158P1D7 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including set forth in Table 1. Consequently, 158P1D7 provides a diagnostic and/or therapeutic target for cancers. The 158P1D7 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: April 15, 2008
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
  • Antibodies to G protein-coupled receptor
    Patent number: 7351583
    Abstract: A novel gene (designated PHOR-1) that is highly over-expressed in prostate and other cancers and its encoded protein are described. PHOR-1 is a G protein-coupled receptor with homology to receptors involved in olfaction. PHOR-1 in normal human tissues is restricted to prostate, and this gene is highly over-expressed in prostate cancer as well as in cancers of the kidney, uterus, cervix, stomach and rectum. Consequently, PHOR-1 provides a diagnostic and/or therapeutic target for prostate cancer.
    Type: Grant
    Filed: November 16, 2004
    Date of Patent: April 1, 2008
    Assignee: Agensys, Inc.
    Inventors: Arthur B. Raitano, Daniel E. H. Afar, Aya Jakobovits, Mary Faris, Rene S. Hubert, Steven Chappell Mitchell, Douglas Saffran
  • 36P6D5: secreted tumor antigen
    Publication number: 20080019971
    Abstract: Described is a gene and its encoded secreted tumor antigen, termed 36P6D5, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers which express 36P6D5, particularly including cancers of the bladder, kidney, prostate, breast, colon, ovary and pancreas.
    Type: Application
    Filed: May 24, 2007
    Publication date: January 24, 2008
    Inventors: Arthur Raitano, Aya Jakobovits, Mary Faris, Daniel Afar, Rene Hubert, Steve Mitchell